Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength
Eli Lilly and Company (NYSE: LLY) reported fourth‑quarter 2025 revenue of USD 19.29 billion, up 43% year‑on‑year (YOY),...
Eli Lilly and Company (NYSE: LLY) reported fourth‑quarter 2025 revenue of USD 19.29 billion, up 43% year‑on‑year (YOY),...
Novartis AG (NYSE: NVS) reported full‑year 2025 net sales of USD 54.5 billion, up 8% year‑on‑year (YOY) at...
Pfizer Inc. (NYSE: PFE) reported full‑year 2025 revenue of USD 62.6 billion, representing a 2% operational decline at constant...
Merck & Co. (MSD, NYSE: MRK) reported full‑year 2025 revenue of USD 65.5 billion, up 2% year‑on‑year...
Sanofi (NASDAQ: SNY) reported full‑year 2025 revenues of EUR 43.626 billion (USD 47.8 billion), representing 9.9% growth at constant exchange...
Roche (SWX: ROG, OTCMKTS: RHHBY) reported full‑year 2025 sales of CHF 61.5 billion : (USD 69.1 billion), representing 7% growth at...
Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc. (NYSE: PEN) announced a definitive agreement for Boston Scientific...
Xellsmart, a Suzhou‑based stem‑cell startup, announced the completion of RMB 400 million (USD 57.3 million) in combined Series B/B+...
Genhouse Bio, a small‑molecule oncology company incubated by Viva Biotech, announced the completion of a...
Guangzhou Baiyunshan Pharmaceutical Co., Ltd (SHA: 600332) announced its intention to acquire 100% equity of...
Xinyuan Zhenghe (Hangzhou) Private Equity Fund Management Co., Ltd., Sirnaomics, and the Fuyang Economic and...
Cellular Origins announced the completion of an over‑subscribed $40 million Series A financing round led by...
D3 Bio, a globally focused biotechnology company, announced the completion of a USD 108 million Series B...
OTR Therapeutics Limited announced the successful completion of a USD 100 million Series A financing,...
Chengdu New Radiomedicine Technology Co., Ltd. announced completion of its Series D financing round, raising...
Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced the establishment of the Wuhan Ruicheng New...
Proviva Therapeutics announced the completion of a Series A+ financing round, raising over USD 30 million led...
Phrontline Biopharma, a next‑generation antibody‑drug conjugate (ADC) company, announced the close of an oversubscribed USD...
BrightGene BrightGene Bio-Medical Techonology (Suzhou) Co., Ltd. (SHA: 688166) disclosed a RMB 50 million (≈ US$7.2 million) capital increase...
Pfizer Inc. (NYSE: PFE) disclosed on November 13, 2025 that it has sold a portion of its...